May Serum Levels of Advanced Oxidized Protein Products Serve as a Prognostic Marker of Disease Duration in Patients with Idiopathic Parkinson's Disease?

García‐Moreno, Jorge; Pablos, Ángel Martín de; García-Sánchez, M. I.; Méndez-Lucena, C.; Damas-Hermoso, Fátima; Rus, Macarena; Chacón, José; Fernández, Emilio

doi:10.1089/ars.2012.5026

Cited by 29 publications

(19 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Garcia‐Moreno et al showed, through enzyme‐linked immune assays (ELISA) that the amount of advanced oxidized protein products (AOPP, a marker for protein halogenation which is the result of free radicals) in CSF increased significantly faster in incubated CSF from PD patients with Hoehn & Yahr (H&Y) score 1–2 compared with H&Y score 3–4 and controls, maybe indicating a susceptibility to oxidative damage in early disease stages. Corroborating this notion, Fernandez et al showed an increase in unspecific 3‐nitrotyrosine protein products (nitrosylation of proteins being an oxidative damage mechanism) in PD patients with H&Y score 1–2 compared with advanced PD and controls.…”

Section: Resultsmentioning

confidence: 99%

Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review

et al. 2016

View full text Add to dashboard Cite

Diagnosis of Parkinson's disease (PD) relies on clinical history and physical examination, but misdiagnosis is common in early stages. Identification of biomarkers for PD may allow early and more precise diagnosis and monitoring of dopamine replacement strategies and disease modifying treatments. Developments in analytical chemistry allow the detection of large numbers of molecules in plasma or cerebrospinal fluid, associated with the pathophysiology or pathogenesis of PD. This systematic review includes cerebrospinal fluid biomarker studies focusing on different disease pathways: oxidative stress, neuroinflammation, lysosomal dysfunction and proteins involved in PD and other neurodegenerative disorders, focusing on four clinical domains: their ability to (1) distinguish PD from healthy subjects and other neurodegenerative disorders as well as their relation to (2) disease duration after initial diagnosis, (3) severity of disease (motor symptoms) and (4) cognitive dysfunction. Oligomeric alpha-synuclein might be helpful in the separation of PD from controls. Through metabolomics, changes in purine and tryptophan metabolism have been discovered in patients with PD. Neurofilament light chain (NfL) has a significant role in distinguishing PD from other neurodegenerative diseases. Several oxidative stress markers are related to disease severity, with the antioxidant urate also having a prognostic value in terms of disease severity. Increased levels of amyloid and tau-proteins correlate with cognitive decline and may have prognostic value for cognitive deficits in PD. In the future, larger longitudinal studies, corroborating previous research on viable biomarker candidates or using metabolomics identifying a vast amount of potential biomarkers, could be a good approach.

show abstract

Section: Resultsmentioning

confidence: 99%

Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Consequently, we speculate that oxidative DNA damage plays a significant role in the pathogenesis of PD. Therefore, the 8-OHdG levels in the CSF and serum of PD patients are significantly higher than normal controls (Gmitterová et al, 2009 ; Isobe et al, 2010 ; García-Moreno et al, 2013 ). Furthermore, the concentrations of 8-OHdG are positively associated with the duration of illness and %CoQ-10 (Isobe et al, 2010 ).…”

Section: Biochemical Biomarkersmentioning

confidence: 99%

Recent Advances in Biomarkers for Parkinson’s Disease

Yan

Guo

et al. 2018

Front. Aging Neurosci.

135

128

View full text Add to dashboard Cite

Parkinson’s disease (PD) is one of the common progressive neurodegenerative disorders with several motor and non-motor symptoms. Most of the motor symptoms may appear at a late stage where most of the dopaminergic neurons have been already damaged. In order to provide better clinical intervention and treatment at the onset of disease, it is imperative to find accurate biomarkers for early diagnosis, including prodromal diagnosis and preclinical diagnosis. At the same time, these reliable biomarkers can also be utilized to monitor the progress of the disease. In this review article, we will discuss recent advances in the development of PD biomarkers from different aspects, including clinical, biochemical, neuroimaging and genetic aspects. Although various biomarkers for PD have been developed so far, their specificity and sensitivity are not ideal when applied individually. So, the combination of multimodal biomarkers will greatly improve the diagnostic accuracy and facilitate the implementation of personalized medicine.

show abstract

“…Five ml of CSF was collected and stored in polypropylene tubes (Eurotube), and rapidly aliquoted, coded, and frozen at -80°C for further analyses. A 1-ml collection in a glass tube was em-ployed to observe the absence of traumatic puncture and to quantify red cells before storing (3). CSF with excess of red cells was discarded ( > 500 red cells/ll).…”

Section: Blood and Csf Collection And Biochemical Measuresmentioning

confidence: 99%

May the Evaluation of Nitrosative Stress Through Selective Increase of 3-Nitrotyrosine Proteins Other Than Nitroalbumin and Dominant Tyrosine-125/136 Nitrosylation of Serum α-Synuclein Serve for Diagnosis of Sporadic Parkinson's Disease?

Fernández

García‐Moreno²,

Pablos³

et al. 2013

Antioxidants & Redox Signaling

Self Cite

View full text Add to dashboard Cite

Nitrosative stress, where nitrosylation of tyrosine (Tyr) leading to 3-nitrotyrosine proteins or free 3-nitrotyrosine is the most prominent change, has been proposed as a pathogenic mechanism in Parkinson's disease (PD). Levels of 3-nitrotyrosine proteins in serum and cerebrospinal fluid (CSF) of patients with PD have not been studied. Nitrosative stress-induced protein changes in serum and CSF were analyzed in patients with PD (n=54) and controls (n=40). Herein, we demonstrate the presence of nitrosative stress in serum and CSF of patients with early PD leading to selective increase of 3-nitrotyrosine proteins other than nitroalbumin, without free 3-nitrotyrosine (Hoehn-Yahr stage 1, p<0.05; stage 2, p<0.01). Among 3-nitrotyrosine proteins, nitro-α-synuclein (N-αSyn) was detected in serum, not CSF, and the sites of Tyr nitrosylation were observed to be modified in patients with early PD. Thus, the intensity of nitrosylation of Tyr125/136 residues is enhanced (stage 1, p<0.05; stage 2, p<0.01), and that of the Tyr39 site is reduced (stage 1, p<0.05), and the ratio between both parameters (α-synuclein with nitrosylated tyrosines 125 and 136 [N-αSyn-Tyr125/136]:α-synuclein with nitrosylated tyrosine 39 [N-αSyn-Tyr39] ratio) is significantly higher in patients with early PD (p<0.01). These observations lead to the hypothesis that evaluating nitrosative stress through enhanced levels of 3-nitrotyrosine proteins in serum and CSF without changes in nitroalbumin, together with the profile of tyrosine nitrosylation of serum αSyn characterized by dominant nitrosylation of Tyr125/136, could serve for the diagnosis of sporadic PD.

show abstract

May Serum Levels of Advanced Oxidized Protein Products Serve as a Prognostic Marker of Disease Duration in Patients with Idiopathic Parkinson's Disease?

Cited by 29 publications

References 8 publications

Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review

Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review

Recent Advances in Biomarkers for Parkinson’s Disease

May the Evaluation of Nitrosative Stress Through Selective Increase of 3-Nitrotyrosine Proteins Other Than Nitroalbumin and Dominant Tyrosine-125/136 Nitrosylation of Serum α-Synuclein Serve for Diagnosis of Sporadic Parkinson's Disease?

Contact Info

Product

Resources

About